Novo Nordisk Acquires Emisphere Tech in $1.8 Billion Deal
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion. Novo Nordisk specializes in diabetes-related therapeutics. Emisphere is a drug delivery company, with products such as Eligen B12, the first and only once-daily oral non-prescription medical food to normalize B12 levels without injection.